Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 5 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Endo International plc | 139,143 | reported | 11 Jun 2021 | tx 23+245,647−116,322 |
| Clearside Biomedical, Inc. | 45,000 | reported | 20 Jun 2024 | tx 15+278,000−40,000 |
| PhaseBio Pharmaceuticals Inc | 37,510 | reported | 19 May 2023 | tx 17+115,660−37,510 |
| BIOCRYST PHARMACEUTICALS INC | 27,181 | reported | 12 Jun 2025 | tx 58+655,987−276,532 |
| CUBIST PHARMACEUTICALS INC | 0 | reported | 21 Jan 2015 | tx 40+118,019−118,019 |
| ENDO PHARMACEUTICALS HOLDINGS INC | 0 | reported | 28 Feb 2014 | tx 19+37,926−51,925 |
| INSPIRE PHARMACEUTICALS INC | 0 | reported | 13 May 2011 | tx 18+121,837−160,059 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 12 Jun 2025 | GRANT_AWARD | BIOCRYST PHARMACEUTICALS INC | 12,500 | 0.00 USD | |
| 12 Jun 2025 | GRANT_AWARD | BIOCRYST PHARMACEUTICALS INC | 27,181 | 0.00 USD | deriv |
| 13 Dec 2024 | SALE | BIOCRYST PHARMACEUTICALS INC | 7,000 | 7.54 USD | |
| 20 Jun 2024 | GRANT_AWARD | Clearside Biomedical, Inc. | 45,000 | 0.00 USD | deriv |
| 12 Jun 2024 | GRANT_AWARD | BIOCRYST PHARMACEUTICALS INC | 6,820 | 0.00 USD | |
| 12 Jun 2024 | GRANT_AWARD | BIOCRYST PHARMACEUTICALS INC | 49,933 | 0.00 USD | deriv |
| 20 May 2024 | PURCHASE | BIOCRYST PHARMACEUTICALS INC | 5,000 | 6.38 USD | |
| 03 Oct 2023 | PURCHASE | Clearside Biomedical, Inc. | 10,000 | 0.86 USD | |
| 22 Jun 2023 | GRANT_AWARD | Clearside Biomedical, Inc. | 30,000 | 0.00 USD | deriv |
| 14 Jun 2023 | SALE | BIOCRYST PHARMACEUTICALS INC | 12,866 | 8.04 USD | |
| 13 Jun 2023 | GRANT_AWARD | BIOCRYST PHARMACEUTICALS INC | 16,745 | 0.00 USD | |
| 13 Jun 2023 | GRANT_AWARD | BIOCRYST PHARMACEUTICALS INC | 39,072 | 0.00 USD | deriv |
| 19 May 2023 | EXERCISE | PhaseBio Pharmaceuticals Inc | 3,750 | — | |
| 19 May 2023 | EXERCISE | PhaseBio Pharmaceuticals Inc | 3,750 | 0.00 USD | deriv |
| 17 Nov 2022 | PURCHASE | Clearside Biomedical, Inc. | 30,000 | 1.33 USD | first after silence |
| 22 Jun 2022 | GRANT_AWARD | Clearside Biomedical, Inc. | 30,000 | 0.00 USD | deriv |
| 07 Jun 2022 | GRANT_AWARD | BIOCRYST PHARMACEUTICALS INC | 12,866 | 0.00 USD | |
| 07 Jun 2022 | GRANT_AWARD | BIOCRYST PHARMACEUTICALS INC | 30,022 | 0.00 USD | deriv |
| 19 May 2022 | GRANT_AWARD | PhaseBio Pharmaceuticals Inc | 17,500 | 0.00 USD | deriv |
| 19 May 2022 | GRANT_AWARD | PhaseBio Pharmaceuticals Inc | 3,750 | 0.00 USD | deriv |
| 05 Nov 2021 | EXERCISE | PhaseBio Pharmaceuticals Inc | 1,500 | 3.15 USD | |
| 05 Nov 2021 | EXERCISE | PhaseBio Pharmaceuticals Inc | 24,860 | 2.26 USD | |
| 08 Nov 2021 | EXERCISE | PhaseBio Pharmaceuticals Inc | 7,400 | 3.15 USD | |
| 08 Nov 2021 | EXERCISE | PhaseBio Pharmaceuticals Inc | 7,400 | 3.15 USD | deriv |
| 05 Nov 2021 | EXERCISE | PhaseBio Pharmaceuticals Inc | 1,500 | 3.15 USD | deriv |
5 purchases reported after at least 12 months of silence — most recent on 17 Nov 2022.